Published in J Clin Oncol on June 14, 2010
Observational Study on Skeletal Ewing's Sarcoma (EWOss) | NCT04845893
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov (2014) 1.63
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol (2013) 1.11
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer (2012) 1.06
A proposed role for neutrophil extracellular traps in cancer immunoediting. Front Immunol (2013) 1.02
Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proc Natl Acad Sci U S A (2015) 0.99
Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas. Clin Sarcoma Res (2012) 0.95
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin Sarcoma Res (2012) 0.94
A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatr Blood Cancer (2012) 0.91
Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications. PLoS One (2014) 0.91
F-18 fluorodeoxyglucose positron emission tomography "super scan" in a patient of metastatic primitive neuroectodermal tumor of the kidney. Indian J Nucl Med (2012) 0.90
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget (2015) 0.89
The ets transcription factor Fli-1 in development, cancer and disease. Oncogene (2014) 0.89
Current therapeutic approaches in metastatic and recurrent ewing sarcoma. Sarcoma (2010) 0.89
Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects. Oncotarget (2013) 0.89
Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. Br J Cancer (2011) 0.89
Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer (2013) 0.88
Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer (2011) 0.87
Ewing sarcoma of the bone in children under 6 years of age. PLoS One (2013) 0.86
Is the Induced-membrane Technique Successful for Limb Reconstruction After Resecting Large Bone Tumors in Children? Clin Orthop Relat Res (2015) 0.86
Paley's multiplier method does not accurately predict adult height in children with bone sarcoma. Clin Orthop Relat Res (2014) 0.86
Multimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the Literature. Sarcoma (2016) 0.83
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant (2011) 0.82
Bone sarcomas: from biology to targeted therapies. Sarcoma (2012) 0.82
Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour. Sarcoma (2010) 0.82
Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes. Int J Mol Sci (2015) 0.82
Radiologic Evaluation of Compressive Osseointegration for the Fixation of Reconstruction Prostheses after Tumor Resection. Biomed Res Int (2015) 0.81
Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. Mol Oncol (2015) 0.80
Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatr Blood Cancer (2015) 0.80
Primary Ewing's Sarcoma/Primitive Neuroectodermal Tumor of of Kidney - a Diagnostic Dilemma. Iran J Cancer Prev (2015) 0.80
Dural metastasis of Ewing's sarcoma. Surg Neurol Int (2013) 0.79
In search of targeted therapies for childhood cancer. Front Oncol (2011) 0.79
Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival. Cancer (2014) 0.79
Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients. Bone Marrow Transplant (2015) 0.79
Targeted therapy in Ewing sarcoma. ISRN Oncol (2012) 0.78
Outcome for children with metastatic solid tumors over the last four decades. PLoS One (2014) 0.77
High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases. Oncotarget (2015) 0.77
Diagnosis and treatment of Ewing sarcoma of the bone: a review article. J Orthop Sci (2015) 0.77
Extraosseous Ewing Sarcoma: Diagnosis, Prognosis and Optimal Management. Indian J Surg (2015) 0.76
Management of Ewing sarcoma family of tumors: Current scenario and unmet need. World J Orthop (2016) 0.76
Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76
Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. BMC Cancer (2015) 0.76
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology (2016) 0.76
Ewing sarcoma of the oral cavity. A review. J Clin Exp Dent (2017) 0.75
Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration. Bone Marrow Transplant (2016) 0.75
Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology. Neuropeptides (2015) 0.75
A patient with scapular Ewing sarcoma; 5-year follow-up after extracorporeal irradiation and re-implantation of the scapula, a case report. J Bone Oncol (2013) 0.75
Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine. Oncotarget (2015) 0.75
Clinical outcomes and prognostic factors of adult's Ewing sarcoma family of tumors: single center experience. Contemp Oncol (Pozn) (2016) 0.75
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors. Korean J Pediatr (2013) 0.75
A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up. Bone Marrow Transplant (2012) 0.75
Synthetic treatment of intracranial peripheral primitive neuroectodermal tumor with multiple metastasis: a case report. Onco Targets Ther (2016) 0.75
UK guidelines for the management of bone sarcomas. Clin Sarcoma Res (2016) 0.75
Is time of the essence? Delayed diagnosis of Ewing's sarcoma. BMJ Case Rep (2015) 0.75
Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy. Cancer Immunol Immunother (2016) 0.75
Primary Renal Primitive Neuroectodermal Tumor/Ewing's Sarcoma Imaging and Pathologic Findings of a Patient with a Nine Year, Eight Month Disease Free Period: Case Report and Review of Literature. Nephrourol Mon (2016) 0.75
Multifocal bone and bone marrow lesions in children - MRI findings. Pediatr Radiol (2016) 0.75
Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. Onco Targets Ther (2017) 0.75
Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist (2017) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol (2002) 10.03
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol (2010) 4.93
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol (2003) 3.93
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29
Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol (2010) 3.27
High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol (2003) 3.14
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Improving child health services in the UK: insights from Europe and their implications for the NHS reforms. BMJ (2011) 2.98
Ewing's sarcoma family of tumors: current management. Oncologist (2006) 2.97
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol (2005) 2.81
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood (2007) 2.61
Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol (2011) 2.60
Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer (2011) 2.49
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol (2009) 2.48
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood (2013) 2.46
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol (2012) 2.29
Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet (2008) 2.24
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov (2003) 2.11
Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study. Eur J Cardiothorac Surg (2010) 2.06
Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol (2008) 1.95
Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood (2002) 1.75
Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys (2003) 1.70
DDT and malaria prevention: addressing the paradox. Environ Health Perspect (2011) 1.70
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer (2006) 1.69
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood (2007) 1.67
Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol (2005) 1.66
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 1.64
Infantile fibrosarcoma: management based on the European experience. J Clin Oncol (2009) 1.62
Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol (2005) 1.59
Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res (2005) 1.55
Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med (2002) 1.53
A molecular map of mesenchymal tumors. Genome Biol (2005) 1.52
Status of legislation and regulatory control of public health pesticides in countries endemic with or at risk of major vector-borne diseases. Environ Health Perspect (2011) 1.52
Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 1.44
In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Haematologica (2005) 1.44
Nutritional status of children and young adults with Ewing sarcoma or osteosarcoma at diagnosis and during multimodality therapy. Pediatr Blood Cancer (2011) 1.44
Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer (2013) 1.43
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol (2003) 1.43
Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys (2006) 1.42
Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab (2007) 1.42
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother (2005) 1.41
Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition? Pediatr Blood Cancer (2006) 1.41
Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J (2013) 1.41
Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol (2012) 1.41
Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Pediatr Blood Cancer (2006) 1.40
Brachytherapy in children with rhabdomyosarcomas of the nasolabial fold. Pediatr Blood Cancer (2014) 1.40
Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr (2005) 1.39
The competent doctor: a paper for discussion. Clin Med (2005) 1.39
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol (2010) 1.36
Lessons from agriculture for the sustainable management of malaria vectors. PLoS Med (2012) 1.34
Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study. Cancer (2011) 1.34
Bone tumors in adolescents and young adults. Curr Treat Options Oncol (2008) 1.33
Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol (2005) 1.28
Modernizing medical careers: a response from the Academy of Medical Royal Colleges. J R Soc Med (2006) 1.27
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol (2009) 1.27
Extra-renal non-cerebral rhabdoid tumours. Pediatr Blood Cancer (2008) 1.26
Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer (2002) 1.25
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol (2010) 1.24
Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group. Oral Oncol (2007) 1.24
Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res (2011) 1.24
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer (2003) 1.24
Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol (2003) 1.23
Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom (2008) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol (2009) 1.19
How frequently do young people with potential cancer symptoms present in primary care? Br J Gen Pract (2011) 1.18
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer (2008) 1.18
Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol (2013) 1.17
Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol (2004) 1.17